Publisher Correction: A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing

Código QR

Publisher Correction: A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing

Guardado en:

Detalles Bibliográficos
Autores principales:	Mahnaz Habibi, Golnaz Taheri, Rosa Aghdam
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/64026e7ad50a48eebceb76e34338b720
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing
por: Mahnaz Habibi, et al.
Publicado: (2021)

Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing
por: Sepideh Sadegh, et al.
Publicado: (2020)

A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing.
por: Nithishwer Mouroug Anand, et al.
Publicado: (2021)

Causal network models of SARS-CoV-2 expression and aging to identify candidates for drug repurposing
por: Anastasiya Belyaeva, et al.
Publicado: (2021)

Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
por: Hanjun Zhao, et al.
Publicado: (2021)

Drug repurposing for coronavirus (SARS-CoV-2) based on gene co-expression network analysis
por: Habib MotieGhader, et al.
Publicado: (2021)

Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase
por: Syed Hani Abidi, et al.
Publicado: (2021)

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.
por: Jeremy D Baker, et al.
Publicado: (2021)

A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection
por: Bernhard Ellinger, et al.
Publicado: (2021)

Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants
por: Isabella A. Guedes, et al.
Publicado: (2021)

Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection
por: Chunyan Wang, et al.
Publicado: (2020)

Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium.
por: Rajaneesh K Gupta, et al.
Publicado: (2021)

Publisher Correction: Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19
por: Martin A. Redhead, et al.
Publicado: (2021)

Identification of potential inhibitors of SARS-CoV-2 S protein–ACE2 interaction by in silico drug repurposing [version 2; peer review: 2 approved]
por: Fabiola E Tristán-Flores, et al.
Publicado: (2021)

Publisher Correction: Standardized preservation, extraction and quantification techniques for detection of fecal SARS-CoV-2 RNA
por: Aravind Natarajan, et al.
Publicado: (2021)

Publisher Correction: Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
por: Rebeca Santano, et al.
Publicado: (2021)

Publisher Correction: Development, evaluation of the PNA RT-LAMP assay for rapid molecular detection of SARS-CoV-2
por: Chinbayar Bat-Ochir, et al.
Publicado: (2021)

Publisher Correction: Quantitative evaluation of SARS-CoV-2 inactivation using a deep ultraviolet light-emitting diode
por: Takeo Minamikawa, et al.
Publicado: (2021)

Author Correction: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
por: Xiuyuan Ou, et al.
Publicado: (2021)

SYNTHETIC BIOLOGY MEETS PRECISION MEDICINE: DRUG REPURPOSING FOR BLOOD CANCER PRECISION MEDICINE
por: Deepak Balaji Thimiri Govindaraj Thimiri Govindaraj
Publicado: (2021)

Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2
por: Qilong Tang, et al.
Publicado: (2021)

Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
por: Bogna Grygiel-Górniak, et al.
Publicado: (2021)

SARS‐CoV‐2–host proteome interactions for antiviral drug discovery
por: Xiaonan Liu, et al.
Publicado: (2021)

Immune‐viral dynamics modeling for SARS‐CoV‐2 drug development
por: Youfang Cao, et al.
Publicado: (2021)

Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates
por: Joana M. O. Santos, et al.
Publicado: (2021)

Coronavirus (SARS-CoV-2): Preventions, keys to diagnosis and treatment of SARS-CoV-2
por: Kuldeep Singh Patel, et al.
Publicado: (2020)

Comparison of the Characteristics of Cytokine Storm and Immune Response Induced by SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections
por: Liu T, et al.
Publicado: (2021)

Author Correction: A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
por: Xuping Xie, et al.
Publicado: (2021)

Drug repurposing for tooth regeneration: The promising premises
por: T C Divya, et al.
Publicado: (2021)

Repurposing benzimidazole and benzothiazole derivatives as potential inhibitors of SARS-CoV-2: DFT, QSAR, molecular docking, molecular dynamics simulation, and in-silico pharmacokinetic and toxicity studies
por: Ranjan K. Mohapatra, et al.
Publicado: (2021)

Testing for SARS-CoV-2
por: Popadić Dušan
Publicado: (2021)

SARS-CoV-2 in cardiomyocytes
por: Josef Finsterer
Publicado: (2021)

Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities
por: Xiaodong Tian, et al.
Publicado: (2021)

Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge.
por: Antonio Muruato, et al.
Publicado: (2021)

Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge
por: Antonio Muruato, et al.
Publicado: (2021)

Point-of-care SARS-CoV-2 serological assays for enhanced case finding in a UK inpatient population
por: S. J. C. Pallett, et al.
Publicado: (2021)

Publisher Correction: Organosilicon uptake by biological membranes
por: Pepijn Beekman, et al.
Publicado: (2021)

Effect of drug metabolism in the treatment of SARS-CoV-2 from an entirely computational perspective
por: João Paulo Almirão de Jesus, et al.
Publicado: (2021)

Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets
por: Su-Jin Park, et al.
Publicado: (2020)

DCcov: Repositioning of drugs and drug combinations for SARS-CoV-2 infected lung through constraint-based modeling
por: Ali Kishk, et al.
Publicado: (2021)